Answers are grounded in this paper and cite their sources.
We found that anakinra, an FDA-approved drug that inhibits IL-1 receptor (IL-1R), when given with or without gemcitabine, can reduce tumor growth by inhibiting IL1α-induced NF-κB activity; this result suggests that it is a useful therapeutic approach for PDAC.
No takes yet. Share an insight, caveat, or question.
Zhuang et al. (2015) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: